CareDx Inc
Rating
Updated: Aug 28, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare provider...
Latest News
14 days ago · zacks.com
Are Medical Stocks Lagging CareDx (CDNA) This Year?Here is how CareDx (CDNA) and Concentra Group (CON) have performed compared to their sector so far this year.
26 days ago · zacks.com
CareDx (CDNA) is a Great Momentum Stock: Should You Buy?Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
28 days ago · zacks.com
Zacks Industry Outlook CareDx, BrightSpring and PACSCareDx, BrightSpring and PACS have been highlighted in this Industry Outlook article.
1 month ago · gurufocus.com
Ron Baron Trims CareDx Inc (CDNA) Stake -- Shares Trade 86% Above GF ValueOn June 30, 2026, Ron Baron (Trades, Portfolio) executed a significant reduction in the firm's position in CareDx Inc (NASDAQ: CDNA), selling 1,399,083 shares at
2 months ago · businesswire.com
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On August 5, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an aggregate of 97,090 shares of common stock. With respect to 34 of the new employees, an aggregate of 93,090 of the RSUs will vest o.
2 months ago · fool.com
Why CareDx Stock Jumped TodayCareDx is helping to improve outcomes for transplant patients. The health monitor's non-invasive tests are in high demand.
2 months ago · seekingalpha.com
CareDx, Inc. (CDNA) Q2 2026 Earnings Call TranscriptCareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript
2 months ago · zacks.com
CareDx (CDNA) Beats Q2 Earnings and Revenue EstimatesCareDx (CDNA) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.1 per share a year ago.
2 months ago · marketbeat.com
CareDx Q2 Earnings Call HighlightsCareDx NASDAQ: CDNA reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began integrating the recently acquired NavDx specialty oncology platform.
2 months ago · zacks.com
CareDx (CDNA) Earnings Expected to Grow: Should You Buy?CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove CDNA